Neil Woodford’s Risky Portfolio, ft. AstraZeneca plc And Imperial Tobacco Group PLC

AstraZeneca plc (LON:AZN), BT Group plc (LON:BT-A), Rolls-Royce plc (LON: RR) and Imperial Tobacco plc (LON:IMT) are a bet on the M&A cycle…

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

AstraZeneca (LSE: AZN), BT Group (LSE: BT-A), Rolls-Royce (LSE: RR) and Imperial Tobacco (LSE: IMT) account for about 23% of Neil Woodford’s new equity portfolio. BAE Systems, Legal & General and Centrica make up for an additional 7%.

Has Mr Woodford lost his mind? No, he has not. His equity income fund portfolio comprises a total of 61 companies. Sifting through the full list, one may argue that Mr Woodford seems to be betting on the current M&A wave more than on fundamentals, however.

AstraZeneca: How Safe Is It?

Astra is the largest holding (8.3%) in Mr Woodford’s portfolio. Astra is not expected to deliver growth in revenue and earnings for some time. It’s a value play, the bulls argue, for shareholders who believe management will meet their long-term projections.

Astra is virtually debt-free and boasts hefty operating margins, which is typical for large pharmaceutical companies. Its most interesting feature: Astra is still a takeover target for Pfizer. The shares are overpriced by about 20% right now, based on fundamentals, in my view.

GlaxoSmithKline (7.1%) is Mr Woodford’s second-largest holding. GSK is not necessarily an M&A play, yet its assets base may change over time — which could benefit shareholders. And GSK stock is dirt cheap.

Tobacco Consolidation & BT

The tobacco industry is already consolidated, but recent M&A talk has placed the spotlight on Imperial Tobacco, which ranks fifth (5.3%) in Mr Woodford’s portfolio. Meanwhile, British American Tobacco ranks third (6.2%), and could be a consolidator.

Elsewhere, BT ranks fourth (6.02%), and this is probably the most surprising name in the top 10. It’s cheap by most metrics, but it’s hard to fathom why anybody would invest in a business whose revenue growth will barely match inflation in the next couple of years. Decent earnings growth is also in doubt. 

BT is a restructuring play, of course. “With a low beta and a 2.6% dividend yield, BT stock will likely mirror the market trends unless it takes a more aggressive stance on investment at this point in the business cycle,” I argued on 9 May, when BT stock traded at about £3.80. The shares now change hands at £3.82.

Will a change in BT’s corporate structure and/or extraordinary corporate activity provide a fillip to shareholders? Mr Woodford may be betting on these elements. 

More To Do Rolls-Royce 

Rolls ranks ninth (3.47%). I believe the company’s appeal comes from recent corporate activity that proved management were eager to reward shareholders by investing proceeds from asset sales into buybacks. As it shrinks, and more disposals occur, Rolls could become a takeover target, too. It boasts a market cap of about £20bn; Rolls could be swallowed by a larger American rival.

Others….

BAE is included just outside the top 10, which begs the question: is Mr Woodford betting on a merger with EADS? It has been a while since rumours about such a tie-up emerged after a failed attempt in 2012.

There’s a lot to like in Mr Woodford’s approach – transparency, for instance. His defensive portfolio, however, could be riskier than it seems at first glance at this point in the M&A cycle. 

Further down, Legal & General (takeover target), Centrica (takeover target), Smith & Nephew (takeover target), Reckitt (break-up candidate), G4S (takeover target), Serco (takeover target), Meggitt (takeover target), Cobham (takeover target) are just a few companies that could likely be involved in M&A, one way or another.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alessandro Pasetti has no position in any shares mentioned. The Motley Fool has recommended shares in GlaxoSmithKline and owns shares in Smith & Nephew.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »